Portal de Periódicos da CAPES

Prognostic significance of XRCC4 expression in hepatocellular carcinoma

2017; Impact Journals LLC; Volume: 8; Issue: 50 Linguagem: Inglês

10.18632/oncotarget.21360

1949-2553

Jun Lü, Xing-Zhizi Wang, Tianqi Zhang, Xiaoying Huang, Jin‐Guang Yao, Chao Wang, Zhonghong Wei, Yun Ma, Xue-Min Wu, Chunying Luo, Qiang Xia, Xi‐Dai Long,

Ubiquitin and proteasome pathways

// Jun Lu 1, 2, * , Xing-Zhizi Wang 2, * , Tian-Qi Zhang 2, * , Xiao-Ying Huang 2 , Jin-Guang Yao 2 , Chao Wang 3 , Zhong-Hong Wei 4 , Yun Ma 5 , Xue-Min Wu 2 , Chun-Ying Luo 2 , Qiang Xia 1 and Xi-Dai Long 1, 2 1 Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, P.R.China 2 Department of Pathology, Youjiang Medical University for Nationalities, Baise 533000, P.R.China 3 Department of Medicine, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, P.R.China 4 Department of Tumor, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, P.R.China 5 Department of Pathology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, P.R.China * These authors have contributed equally to this work Correspondence to: Xi-Dai Long, email: sjtulongxd@263.net Keywords: XRCC4, hepatocarcinoma, prognosis, TACE Received: May 01, 2017 Accepted: August 29, 2017 Published: September 28, 2017 ABSTRACT Background: Our previous investigations have shown that the variants of X-ray repair complementing 4 (XRCC4) may be involved in hepatocellular carcinoma (hepatocarcinoma) tumorigenesis. This study aimed to investigate the possible prognostic significance of XRCC4 expression for hepatocarcinoma patients and possible value for the selection of transarterial chemoembolization (TACE) treatment. Materials and Methods: We conducted a hospital-based retrospective analysis (including 421 hepatocarcinoma cases) to analyze the effects of XRCC4 on hepatocarcinoma prognosis and TACE. The levels of XRCC4 expression were tested using immunohistochemistry. The sensitivity of cancer cells to anti-cancer drug doxorubicin was evaluated using the half-maximal inhibitory concentration (IC50). Results : XRCC4 expression was significantly correlated with pathological features including tumor stage, liver cirrhosis, and micro-vessel density. XRCC4 expression was an independent prognostic factor of hepatocarcinoma, and TACE treatments had no effects on prognosis of hepatocarcinoma patients with high XRCC4 expression. More intriguingly, TACE improved the prognosis of hepatocarcinoma patients with low XRCC4 expression. Functionally, XRCC4 overexpression increased while XRCC4 knockdown reduced the IC50 of cancer cells to doxorubicin. Conclusions : These results suggest that XRCC4 may be an independent prognostic factor for hepatocarcinoma patients, and that decreasing XRCC4 expression may be beneficial for post-operative adjuvant TACE treatment in hepatocarcinoma.